Loading
Latest filing published 30 May 2025 for Checkpoint Therapeutics, Inc..
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
This profile gathers the share dealings of Barry M. Salzman in Checkpoint Therapeutics, Inc., where the filings describe the role as board member. In total, 12 filings cover trades dated from 15 June 2017 to 30 May 2025.
Not one of the filings records a straightforward purchase or sale on the market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
The newest entry dates from 30 May 2025: a transaction, in Checkpoint Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
6 of 6 declarations